Bioburden Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
- Transparency Market Research
Bioburden is defined as the number in terms of percentage, colony or cell count of bacteria that thrive on a given unsterilized surface. Bioburden testing, also known as microbial limit testing provides quantification of the bacterial cell cultures on a given unsterilized surface. The major application of bioburden testing lies in implant fixation procedures that require testing ofcertain tolerable bioburden limit before implantation in the human body. The standard for bioburden testing in the US is regulated by the US FDA, whereas global standards are maintained by the ISO (International Organization for Standardization). The quantification for the standardization process is done in terms of colony forming unit (CFU). Bioburden testing is essential in limiting the presence of infection causing bacteria in an object that is to be integrated into a human body as an implant. The testing is important to eliminate the presence of bacterial residue and growth in any object present in natural state. In addition it is almost impossible to remove bacterial residue permanently in an object that is liable to be exposed to open air. Hence sterilization process is performed on an implant object or a device post understanding the bioburden limit. This helps to select the appropriate sterilization technique in order to remove the bacterial burden just prior to the medical (Or other related) procedure. Bioburden testing has therefore saved numerous lives.
Based on technology, bioburden testing is segmented into microbial filter method, advanced colorimetric method, and plate count method. Among these, microbial filter method is the most commonly used method for bioburden testing procedures. The plate count method is among the oldest methods for bioburden testing, however is not used regularly on a large scale commercial basis due to its time consuming procedure. Advanced colorimetric method is presently the most promising and widely used bioburden testing technology. The congregation of colometer and computational capabilities has enabled advanced colometric methods to deliver quick results of quantifying bioburden.
Based on equipment, bioburden testing market can be segmented into PCR (polymerase chain reaction) instruments, cell counters, and automated microbial identification systems that are software integrated. Application segment for bioburden testing includes healthcare, aerospace (satellite production & development), supercomputer (super- microprocessor manufacturing) designing, and others (raw material, equipment cleaning, food & beverage). The healthcare industry is the largest application area of bioburden testing.
Geographically, the bioburden testing market is primarily concentrated in the North America and Asia Pacific region. The demand for bioburden testing in the Asia Pacific region is expected to grow, and very likely to replace the North America market soon. Australia, Japan, and China form the largest markets in the Asia Pacific region. South Asia and South East Asia on the other hand show great potential in terms of life sciences and raw material applications; although at present a majority of the growing bioburden testing market consists of life science applications. Besides this, a large number of contract manufacturers reside in the Asia Pacific region. On the other hand, European industries continue to remain a strong point in the global bioburden testing market mainly due to the high quality of products services offered, presence of numerous quality manufacturers and their increased reliability. However certain significant restrictions for bioburden testing remains valid in the European and North American region, such as dearth of trained technicians, overwhelming volume of service demand, and high cost of services, to name a few. The bio-burden testing market in the Rest of the World (ROW) region is expected to grow at a steady rate, albeit slower than the major economies of the world.
Some of the well known manufacturers/service providers of bioburden testing equipment/service include: Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, SGS S.A., WuXi PharmaTech (Cayman), and Inc., Merck & Co., Inc., Becton, Dickinson and Company, North American Science Associates, Inc., Nelson Laboratories, Pacific Biolabs, and ATS Labs, Inc.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Biotechnology
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017